Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul;183(1):7-8.
doi: 10.1111/bjd.18869. Epub 2020 Feb 3.

Secukinumab in patients with psoriasis who have responded inadequately to tumour necrosis factor inhibitor treatment

T-F Tsai  1
Affiliations
Comment

Secukinumab in patients with psoriasis who have responded inadequately to tumour necrosis factor inhibitor treatment

T-F Tsai. Br J Dermatol. 2020 Jul.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Ger TY, Huang YH, Hui RC et al. Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Ther Adv Chronic Dis 2019; 10:2040622319843756.
    1. Warren RB, Barker JNWB, Finlay AY et al. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE). Br J Dermatol 2020 183:60-70.
    1. Langley RG, Tsai TF, Flavin S et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol 2018; 178:114-23.
    1. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med 2014; 371:326-38.
    1. Kavanaugh A, McInnes IB, Mease PJ et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol 2016; 43:1713-17.

MeSH terms

Substances